Rosiglitazone Maleate

CHEMBL843 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

473.5 g/mol

LogP

—

Phase

4

The maleate salt formulation of rosiglitazone used to improve blood sugar control in type 2 diabetes by activating PPAR-gamma receptors that regulate glucose and fat metabolism. It is used with caution and close monitoring due to potential cardiovascular risks.

Molekularmasse

473,5000 g/mol

TPSA

171,00 Å²

Therapeutische Bereiche

Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hyperlipidemia Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Malaria HIV/AIDS Hepatitis C Heart Failure Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O

InChI

InChI=1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-

Molecular Formula

C22H23N3O7S

HBD / HBA

3 / 10

Rotierbare Bindungen

9

Schwere Atome

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The maleate salt formulation of rosiglitazone used to improve blood sugar control in type 2 diabetes by activating PPAR-gamma receptors that regulate glucose and fat metabolism. It is used with caution and close monitoring due to potential cardiovascular risks.

Yes, Rosiglitazone Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL843. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5281055. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Rosiglitazone Maleate auf PillFYI

Struktur

Schnelldaten

Formel: C22H23N3O7S
Synonyme: 2

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.